February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
Read More...
Tags:
♫ Posted in Blindness | | Comments Off»
February 15th, 2025 2:46 am
-Interim clinical study updates for the first three Subjects treated with BB-301 in the Phase 1b/2a Clinical Treatment Study to be presented as a late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- -Interim clinical study updates for the first three Subjects treated with BB-301 in the Phase 1b/2a Clinical Treatment Study to be presented as a late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025-
See the article here:
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association...
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
February 15th, 2025 2:46 am
MADRID and CAMBRIDGE, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the final results of the Phase IIa REIMAGINE study, which evaluated the safety and efficacy of vafidemstat on aggression in adult patients with borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (ADHD), and autistic spectrum disorder (ASD), were published online in Psychiatry and Clinical Neurosciences. A summary of the final data from this study had been previously released at the 2020 European Psychiatry Association (EPA) annual meeting.
Read the rest here:
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»
February 15th, 2025 2:46 am
COPENHAGEN, Denmark, February 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has received confirmation from the Nasdaq Stock Market LLC (“Nasdaq”) that it has re-established compliance with Nasdaq’s minimum stockholders’ equity requirement. Nasdaq has withdrawn its determination to delist Evaxion, and the company will remain listed as fully compliant with Nasdaq’s rules.
Visit link:
Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination
Read More...
Tags:
♫ Posted in Global News Feed | | Comments Off»